NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia

被引：3
|
作者：
Miller, Whitney [1 ]
Holden, Joanne [1 ]
George, Elisabeth [1 ]
Stein, Ken [1 ]
机构：
[1] NICE Ctr Hlth Technol Evaluat, London WC1V 6NA, England
来源：
LANCET ONCOLOGY | 2011年 / 12卷 / 04期
关键词：
D O I：
10.1016/S1470-2045(11)70066-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：326 / 327
页数：2
相关论文
共 50 条
  • [1] Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
    Edlin, R.
    Connock, M.
    Tubeuf, S.
    Round, J.
    Fry-Smith, A.
    Hyde, C.
    Greenheld, W.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 69 - 74
  • [2] Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia
    Scott, Lesley J.
    [J]. DRUGS, 2016, 76 (08) : 889 - 900
  • [3] Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia
    Lesley J. Scott
    [J]. Drugs, 2016, 76 : 889 - 900
  • [4] Multiple drugsChronic myelomonocytic leukaemia, myelodysplastic syndromes or acute myeloid leukaemia: 8 case reports
    [J]. Reactions Weekly, 2017, 1661 (1) : 230 - 230
  • [5] Azacitidine A Review of its Use in the Management of Myelodysplastic Syndromes/Acute Myeloid Leukaemia
    Keating, Gillian M.
    [J]. DRUGS, 2012, 72 (08) : 1111 - 1136
  • [6] SAFETY PROFILE OF AZACITIDINE IN THE TREATMENT OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKAEMIA
    Minoia, C.
    Sgherza, N.
    Greco, G.
    Buquicchio, C.
    Loseto, G.
    de Fazio, V.
    Iacobazzi, A.
    Rana, A.
    Merchionne, F.
    Tarantini, G.
    Pavone, V.
    Guarini, A.
    [J]. HAEMATOLOGICA, 2014, 99 : 619 - 619
  • [7] DNMT3A mutations are rare in childhood acute myeloid leukaemia, myelodysplastic syndromes and juvenile myelomonocytic leukaemia
    Norio, Shiba
    Taki, Tomohiko
    Park, Myoung-ja
    Shimada, Akira
    Sotomatsu, Manabu
    Adachi, Souichi
    Tawa, Akio
    Horibe, Keizo
    Tsuchida, Masahiro
    Hanada, Ryoji
    Tsukimoto, Ichiro
    Arakawa, Hirokazu
    Hayashi, Yasuhide
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 413 - 414
  • [8] Erratum to Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia
    G. M. Keating
    [J]. Drugs, 2012, 72 : 1578 - 1578
  • [9] Azacitidine/cisplatin/hydroxycarbamideMyelodysplastic/myeloproliferative neoplasm transformed into chronic myelomonocytic leukaemia and then acute myeloid leukaemia: case report
    [J]. Reactions Weekly, 2015, 1555 (1) : 28 - 28
  • [10] Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme
    van der Helm, Lieke H.
    Alhan, Canan
    Wijermans, Pierre W.
    Kooy, Marinus van Marwijk
    Schaafsma, Ron
    Biemond, Bart J.
    Beeker, Aart
    Hoogendoorn, Mels
    van Rees, Bastiaan P.
    de Weerdt, Okke
    Wegman, Jurgen
    Libourel, Ward J.
    Luykx-de Bakker, Sylvia A.
    Minnema, Monique C.
    Brouwer, Rolf E.
    Boer, Fransien Croon-de
    Eefting, Matthijs
    Jie, Kon-Siong G.
    de Loosdrecht, Arjan A. van
    Koedam, Jan
    Veeger, Nic J. G. M.
    Vellenga, Edo
    Huls, Gerwin
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (05) : 599 - 606
12345